IP Library › Granted Patent US 11,859,252
Granted Patent B2
US 11,859,252 · App. 16/644,902 · Granted Jan 2, 2024

Diagnostic and therapeutic methods for cancer

Inventors: Christiaan Nicolaas Klijn (San Francisco, CA); Shiva Malek (Burlingame, CA); Ivana Yen (Millbrae, CA)
Assignee: Genentech, Inc.
C12Q1/6886A61K31/519A61K31/553A61K45/06A61P35/00C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,859,252
App. No.
16/644,902
Granted
Jan 2, 2024
Kind
B2
Abstract

The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).

Claims (8)

1. A method of treating an individual having melanoma, the method comprising:

(a) screening a sample from the individual for a KRAS-G13D mutation, wherein the individual has been determined to have a KRAS-G13D mutation; and

(b) administering a therapeutically effective amount of a pan-RAF dimer inhibitor and a MEK inhibitor to the individual based on the presence of a KRAS-G13D mutation determined in step (a),

wherein the pan-RAF dimer inhibitor is HM95573 and the MEK inhibitor is cobimetinib (GDC-0973).

2. A method of treating an individual having a melanoma, the method comprising administering to the individual a therapeutically effective amount of a pan-RAF dimer inhibitor and a MEK inhibitor, wherein prior to treatment a sample from the individual has been screened for a KRAS-G13D mutation and the presence of a KRAS-G13D mutation in the sample has been determined, and wherein the pan-RAF dimer inhibitor is HM95573 and the MEK inhibitor is cobimetinib (GDC-0973).

3. The method of claim 1 , wherein screening comprises amplifying and sequencing all or a portion of the KRAS gene.

4. The method of claim 1 , wherein the sample is a tissue sample, a cell sample, a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

5. The method of claim 2 , wherein the sample is a tissue sample, a cell sample, a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

Continuity (2)
Provisional Application 62556277 · Sep 8, 2017
Related Publication 20200190596A1 · Jun 18, 2020